Badger Meter is a stock, not an ETF, and it carries broad but divided sell-side coverage. Eight verified, current price targets were reviewed, spanning roughly $112 to $187. The arithmetic mean of all eight is about $163 — only about 5% above the latest close, which does not represent a meaningful hurdle. Accordingly, the central target used here is the average of the six targets that sit above the current price: RBC Capital ($187), Seaport Global ($175), Baird ($175), Argus Research ($170), J.P. Morgan ($170), and Stifel ($168). That average is roughly $174, rounded to $175. In my view, this focused average gives a clearer sense of where upside potential lies.
Views diverge sharply. The bulls — RBC, Seaport, Baird, Argus, J.P. Morgan, and Stifel — generally cite margin expansion, software and AMI (advanced metering infrastructure) growth, and strong cash generation. Barclays is the notable dissenter, holding an Underweight rating with a $112 target on valuation concerns, while Northcoast's $148 target sits below the current price. Most recent actions were post-earnings target increases, including RBC raising to $187 from $162 and Argus upgrading to Buy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Shares recently closed near $154.72. Reaching $175 would require a gain of roughly 13%, a substantial but not extreme move for a high-multiple industrial-technology name. The company reported third-quarter EPS of $1.24, up about 4% year over year and ahead of estimates, with an operating margin near 20.2%, even though revenue of roughly $235.9 million was essentially flat. Full-year revenue is expected to be roughly flat to slightly lower versus 2025, so the near-term story rests on margins, pricing, and mix rather than rapid top-line growth.
The stock trades below its 52-week high near $187, which is the key resistance zone and coincides with the highest analyst target. Support sits near $150 and again in the $140s. A sustained move toward $175 would require clearing the $168–$175 area just beneath the prior peak, making that region the critical technical test. From what I see, monitoring these levels closely helps frame realistic expectations.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms differ. Investors should watch quarterly results and forward guidance, gross and operating margin trends, AMI and software adoption, dividend news, analyst revisions, and interest-rate moves that influence high-multiple stocks.
I rely on AI Daily Buy/Sell Signals as part of my routine to track stocks like BMI. These tools apply artificial intelligence to scan thousands of names in real time, surfacing Buy, Sell, or Hold signals based on price action, momentum, and volume shifts. For a name where sentiment can change quickly around earnings and valuation debates, they help highlight potential turning points and keep an eye on existing positions without sifting through noise manually.
The $175 central target reflects the average of six analyst targets above the current price, not a guarantee. It requires a move of about 13% from roughly $154.72, back toward the stock's prior 52-week high. Support comes from margin momentum, smart-water demand, and recent analyst upgrades, while the principal obstacles are a rich valuation, near-flat revenue, and one prominent bearish target well below the stock. With targets ranging from $112 to $187, the disagreement is wide, and the outcome will likely hinge on whether margin and AMI momentum can offset a premium multiple. No definitive forecast is warranted; investors should weigh the evidence and monitor earnings and analyst revisions closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for BMI crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMI as a result. In 55 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
BMI moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMI advanced for three days, in 184 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 110 of 211 cases where BMI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
The 10-day RSI Indicator for BMI moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 15 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 63 cases where BMI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for BMI turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 23 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
BMI broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BMI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 49 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.714) is normal, around the industry mean (1.448). P/E Ratio (36.786) is within average values for comparable stocks, (5.350). Projected Growth (PEG Ratio) (2.931) is also within normal values, averaging (5.470). Dividend Yield (0.011) settles around the average of (0.012) among similar stocks. P/S Ratio (4.255) is also within normal values, averaging (32.028).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of flow measurement and control products
Industry ElectronicEquipmentInstruments